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Background: Cardiovascular disease (CVD) is the leading cause of early death worldwide, responsible for an
estimated 29% of all global deaths. Reducing salt intake lowers blood pressure and risk of secondary cardiac events.
However, identifying low salt foods can be challenging. SaltSwitch is a simple smartphone application (app) that
enables shoppers to scan the barcode of packaged foods and receive an immediate, interpretive, traffic light
nutrition label on the screen, along with suggestions for healthier lower-salt alternatives. A growing body of
evidence suggests mobile technologies can support healthy behaviour change. However, robust evidence for the
impact of smartphone interventions is lacking. This manuscript outlines the rationale and methods for a randomized
controlled trial designed to determine the effectiveness of SaltSwitch in supporting people with CVD to make
lower-salt food choices.
Design/Methods: A 6-week, two-arm, parallel, randomized controlled trial is being undertaken in New Zealand
(2 weeks baseline and 4 weeks intervention). Three hundred adults aged 40 years and older with CVD and their
main household shoppers are recruited from research lists, cardiac rehabilitation clinics, and communities in
Auckland. Participants are randomized to receive either the SaltSwitch smartphone app or no intervention (control).
Randomisation is stratified by ethnicity and age. The primary outcome is the salt content of household food
purchases. Secondary outcomes are the saturated fat and energy content of household food purchases, household
food expenditure, use and acceptability of the SaltSwitch app by shoppers, and urinary sodium and blood pressure
of participants with CVD. Ambulatory blood pressure and potential longer-term impact (12 weeks) of SaltSwitch will
be assessed in sub-studies (n ~ 40 and n ~ 20, respectively). Household purchases of salt and other nutrients will be
assessed using till receipt data electronically linked with branded food composition data.
Discussion: The results of the SaltSwitch trial will determine the effectiveness, use and acceptability of a
smartphone application to support lower salt food choices and secondary prevention of CVD.
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Cardiovascular disease (CVD) is the leading cause of early
death worldwide, being responsible for an estimated 15.6
million or 30% of all global deaths in 2010 [1]. In 2010,
the number of years of life lost (YLLs) due to CVD and
circulatory diseases was more than 273 million globally
[1]; in New Zealand, CVD accounted for 17.5% (~167,000)
of annual disability adjust life years, and Māori (indigen-
ous New Zealanders) and Pacific peoples, and those living
in lower socio-economic areas were disproportionately af-
fected [2].
Secondary prevention is a vital strategy to reducing
the global and national CVD burden, as 60% of hospita-
lisations occur in people who have been admitted for
CVD in the past five years [3]. For people with CVD, ad-
herence to a heart healthy diet has benefits additive to
drug therapy and is associated with a reduction in mor-
tality of between 8 and 45% [4-7]. Salt reduction is a key
component of a heart healthy diet yet global and national
salt intakes, particularly in high income countries, are
far above recommended guidelines [8]. In New Zealand,
population salt intake is ~9 g/day [9], almost twice the
2012 WHO recommendation and the recommended upper
level of intake in NZ (5 g/day) [10,11].
Cardiac rehabilitation programmes that offer dietary
advice to people with CVD are provided by hospitals
and non-government organisations in many countries,
including New Zealand. However, they are resource in-
tensive and uptake is generally low, largely due to access
issues [12]. Furthermore, many people with CVD find it
difficult to identify low salt food choices because nutri-
tion labeling is confusing [13]. Smartphone technology
may offer a more accessible, cost effective way of deliver-
ing nutrition interventions to cardiac patients. In New
Zealand approximately two-thirds of the adult popula-
tion owns a smartphone [14], and ownership is similar
by ethnicity and income [15,16]. Moreover, thousands of
health and wellness applications (apps) are available dir-
ect to the public. Therefore, it is likely that smartphones
will become synonymous with the future of patient self-
care [17,18].
SaltSwitch is a feature of the FoodSwitch smartphone
app currently available in Australia, New Zealand, and
the United Kingdom, designed to help consumers make
healthier food choices [19]. FoodSwitch and SaltSwitch
enable users to scan the barcode of packaged foods and
receive an immediate interpretive, traffic light nutrition
label on screen, along with a list of healthier lower-salt
alternatives to ‘switch’ to (Figure 1). The main difference
between FoodSwitch and SaltSwitch is an additional cri-
terion in the algorithm used to determine healthier op-
tions [20]. The generic FoodSwitch algorithm allocates
foods with a score based on their overall nutritional pro-
file, and the additional criterion for SaltSwitch ensuresthat healthier alternatives are always lower in salt than
the product scanned. SaltSwitch is not yet available in
New Zealand, but it is available in the UK and Australia
where it has proven functionality and consumer accept-
ability [21].
A growing body of evidence indicates that mobile tech-
nology can support behaviour change [22], yet robust
evidence for smartphone interventions is lacking. This
manuscript outlines the rationale and methods for a ran-
domized controlled trial designed to determine the effect-
iveness of SaltSwitch in supporting people with CVD to
make lower-salt food choices. The primary hypothesis is
that four weeks’ intervention with SaltSwitch will reduce
the salt content of household food purchases compared
with control. Secondary hypotheses are that four weeks’
intervention with SaltSwitch will reduce the saturated
fat and energy content of household food purchases, and
the systolic blood pressure and salt intakes (measured
by urinary sodium excretion) of participants with CVD.
The SPIRIT checklist for Standardised Protocol Items was
followed in writing this manuscript [23] and the proto-
col described reflects the most recent version (Version 2
dated 12th May 2014).
Methods/Design
Trial design
This study is a six-week, two-arm, parallel, randomized
controlled trial (two weeks baseline and four weeks inter-
vention; Figure 2) with a superiority design.
Aims
The primary aim is to determine the effect of the Salt-
Switch smartphone app on the salt content of food pur-
chases made by households where at least one member
has diagnosed CVD. Secondary aims are to evaluate the
effect of SaltSwitch on: (1) saturated fat and (2) energy
content of food purchases made by households; and
(3) systolic blood pressure and (4) urinary sodium of
participants with CVD. Household food expenditure, and
use and acceptability of the SaltSwitch app by shoppers
will also be assessed. Ambulatory blood pressure of
participants with CVD and potential longer-term im-
pact (12 weeks) of SaltSwitch will be assessed in two
sub-studies (n ~ 40 and n ~ 20, respectively).
Participants
Trial participants include individuals with CVD who
complete most of the grocery shopping for their house-
hold, and pairs of individuals, one with CVD and the other
who completes most of the grocery shopping. Only one
person with CVD from each household may take part. Par-
ticipants with CVD are men and women aged 40 years and
older with a previous diagnosis of CVD (history of prior
acute coronary syndrome, revascularization, or exertion
Figure 1 The SaltSwitch smartphone application.
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person) must be 18 years and older, own or have access to
a smartphone (iPhone or Android), and shop at the super-
market for household food at least once per week, spend-
ing $25 or more per household member.
Participants with CVD must not have suffered a cardiac
event in the past three months, been diagnosed with heart
failure or severe valve disease, be on a physician superviseddiet or unwilling to make dietary changes, or be taking any
medication that may lead to hyponatraemia or fluid reten-
tion (frusemide, regular non-steroidal anti-inflammatory
(NSAID) use (excluding aspirin), or regular prednisone
use). A cardiac event is defined as hospitalization for
a heart attack, coronary artery revascularization, stroke, or
heart failure. Main household shoppers must not cur-
rently use the FoodSwitch smartphone app or plan to use




Exclude those not 
meeting initial eligibility 
criteria













10-week follow up 





10-week follow up 
sub study 2 
(n=15)
Main study & sub 
study 1 follow-up 
(week 6)
Main study & sub 
study 1 follow-up 
(week 6)
Sub study 2 
follow-up (n 
week 12)







Figure 2 SaltSwitch trial design.
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planning on going away from home (vacation or other-
wise) for more than three days in the next six weeks.
Recruitment
Potentially eligible participants are invited to take part in
the study via advertisements in supermarkets, hospital
waiting rooms, healthcare organization newsletters, com-
munity newspapers, and other public spaces, and through
social media (Facebook and Twitter). Research assistants
also identify potential participants using an existing
University of Auckland database comprising people with
diagnosed CVD who previously agreed to be contacted for
future research, a market research panel, and through car-
diac rehabilitation clinics. Research assistants provide all
potential participants with a summary of the trial over the
phone to determine their interest in taking part. Those
agreeing to participate are screened for eligibility and sent
a study pack including a participant information sheet
and consent form. Interested and eligible participants are
allocated a unique study registration number including a
household code (001 to 300), a number to indicate whether
there are one or two people participating in the household
(1 or 2), and a code to indicate whether they are the pri-
mary participant with CVD (1), or the secondary partici-
pant (main household shopper; 2). Participants with CVD
are scheduled for a baseline assessment. Main householdshopper participants who do not have CVD are sent a link
in an email to complete an on-line questionnaire.
Sample size
The target sample size of 300 participants with CVD
(150 per group) will provide 80% power at 5% level of
significance (two-sided) to detect a treatment difference
of 0.07 g/MJ (~10%) of salt in household food purchases,
between the two groups at follow up (average over weeks
five and six) assuming a standard deviation of 0.22 g/MJ.
The target sample size was estimated using data on base-
line purchases of salt (mean (SD), 285 (88) mg/MJ) made
by participants in a previous supermarket intervention
trial (n = 1,104) in New Zealand [24] and estimated inter-
vention effects from the Dietary Approaches to Stop
Hypertension study [25].
Ethical approval
Ethical approval was obtained from The University of
Auckland Human Participants Ethics Committee on 16th
December 2013 (reference number 010998).
Randomisation and blinding
Randomisation is undertaken at week two, following
completion of the baseline period. During baseline, par-
ticipants with CVD complete one clinic assessment (see
measurement of outcomes section), and main household
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beverages to provide information on baseline shopping
habits. Participants with CVD and their main household
shoppers (this may be the same person) are excluded prior
to randomisation if they spend < $25/household member
per week on groceries/food or return less than two till re-
ceipts over the baseline period.
At the end of week two, eligible participants are ran-
domized on a 1:1 ratio to receive either the SaltSwitch
smartphone app or control (no intervention). Randomisa-
tion is stratified by ethnic (Māori and non-Māori) and age
(40 to 59 years, and 60 years+) groups using variable block
sizes. The randomisation lists are computer generated and
sealed in individual opaque envelopes by an independent
research assistant. The allocation sequence was generated
and overseen by the study statistician (YJ). Envelopes are
stored in a locked cabinet not accessible to the study stat-
istician or Investigators. A study research assistant chooses
a numbered envelope in sequential order from the correct
stratum. Once allocated, the participant registration num-
ber is recorded on a sheet inside the envelope. Used enve-
lopes are marked and placed at the back of the pile.
Participants are telephoned to advise them of the group
they have been allocated to.
Unique participant randomisation numbers ensure the
study statistician is blinded to treatment allocation. How-
ever, due to the nature of the intervention it is not possible
to blind participants or outcome assessors, and unblinding
procedures are not relevant/required.
Intervention
The intervention group receives the SaltSwitch smart-
phone app for four-weeks. SaltSwitch enables the user to
scan the barcode of packaged foods and beverages using
the phones camera and receive an immediate interpretive,
traffic light nutrition label on screen, along with a list of
healthier lower-salt alternatives to ‘switch’ to (Figure 1).
The New Zealand SaltSwitch app is underpinned by a
database of ~13,000 barcodes and nutritional informa-
tion for packaged foods and non-alcoholic beverages for
sale in supermarkets and convenience stores [26]. Data
are collected annually by fieldworkers [26]. SaltSwitch
also incorporates crowd-sourcing; when a user scans the
barcode of a product not already in the database, they
are prompted to take three photographs (one each for
the front of the pack, the nutrition information panel,
and the ingredient list). Photographs are then sent to the
research team and new products are subsequently added
to the app.
The traffic light labels are determined using the United
Kingdom’s Guidance for creating a front of pack nutri-
tion label for pre-packaged foods [27], and healthier options
are determined using the Australia New Zealand Food
Standards Agency Nutrient Profiling Scoring Calculator(NPSC), a nutrient profiling model (scoring system to rank
foods) used to determine whether foods are eligible to carry
nutrition and health claims in Australia and New Zealand
[20]. The NPSC system allocates a score to food products
by balancing positive nutrients such as fibre and protein
with negative nutrients including salt and saturated fat.
Main household shoppers in the intervention group
are sent a link to download the SaltSwitch app to their
smartphone, and are provided with a telephone tutorial.
Intervention shoppers receive a reminder text message
each week and are encouraged to use the app when
shopping for household food and beverages.
Control
Those randomised to the control group continue to
shop as normal, and are able to access cardiac rehabilita-
tion services as per usual care for people with CVD in
New Zealand. Participants in the control group are ad-
vised on enrolment that they will be offered SaltSwitch
on completion of the trial.
Primary outcome
The primary outcome is the salt content of household
food purchases (g/MJ) at the end of intervention (weeks
five and six).
Secondary outcomes
Saturated fat (g/MJ), energy content (kJ/MJ), and ex-
penditure ($/MJ) on household food purchases will be
assessed at the end of intervention (weeks five and six).
Systolic blood pressure, ambulatory blood pressure (sub-
study 1; n ~ 40), and urinary sodium of the household
member with CVD, and use and acceptability of the
SaltSwitch app (main household shopper) will be
assessed at baseline (week 0) and end of intervention
(week 6). With the exception of ambulatory blood pres-
sure, all outcomes will be assessed over the longer-term,
at weeks 11 and 12, in a sub-group of ~20 people with
CVD (and their main household shopper where applic-
able) who remain enrolled in the study (sub-study 2).
Serious adverse events (SAEs) will be recorded for the
duration of the study.
Measurement of study outcomes
Outcome measurements for participants with CVD are
undertaken in clinics at one of two locations; either the
University of Auckland, or Auckland Hospital. A re-
search assistant telephones each participant to arrange a
convenient time and venue of choice for baseline, week
6, and week 12 assessments (Figure 2). Main household
shoppers who do not have CVD are also encouraged to
attend. On arrival at the clinic, the researcher explains
procedures, answers any questions, and collects consent
forms (baseline only). Height, weight, blood pressure
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complete two on-line questionnaires. Main household
shoppers who are present at clinic appointments also self-
complete baseline and follow-up questionnaires; those not
present are sent a link to their questionnaire in an email.
Primary outcome: the salt content of household food
purchases will be assessed using supermarket till receipts
linked to brand-specific food and nutrient information
from the SaltSwitch app (see Intervention section). Main
household shoppers are provided with a receipt collec-
tion box and return address, postage paid envelopes to
return all till receipts for household food and beverages
purchased during the trial. All till receipts are photo-
graphed and uploaded to a bespoke web-based data entry
system that stores data on all purchased foods and bever-
ages and their costs. The number of purchased items not
included in the SaltSwitch food and nutrient database will
be recorded and included in analyses.
Secondary outcomes: the saturated fat and energy con-
tent of household food purchases, and expenditure on
food, will be assessed using data from till receipts, as de-
scribed for the primary outcome.
Weight, height, blood pressure and urine samples are col-
lected using standard procedures. Weight is measured on a
Salter scale to the nearest 0.1 kg and height is measured on
a stadiometer to the nearest cm. Blood pressure of partici-
pants with CVD (mean of three readings taken at least 3 mi-
nutes apart) is assessed seated, after 10 minutes rest, using
an OMRON automatic blood pressure monitor. Partici-
pants with an average blood pressure >160/90 mmHg, with
an average systolic blood pressure <90 mm/Hg, or who re-
port dizziness when going from sitting to standing, are ad-
vised to discuss this with their General Practitioner. Prior
to commencement of the trial and annually thereafter, the
Salter scales and OMRON automatic blood pressure moni-
tor were serviced and verified according to manufacturer
recommendations.
Participants in sub-study 1 assessing ambulatory blood
pressure are provided a calibrated Mobil-O-Graph
Ambulatory 24-hour Blood Pressure Monitoring System
and instructions. Sub study 1 participants are instructed
to wear the monitor for one 24-hour period within the fol-
lowing five days and keep a diary to record events such as
bed and wake-up times. Ambulatory blood pressure will
be analysed using programming software for the Mobil-
O-Graph.
Twenty-four hour urinary sodium excretion is consid-
ered the gold standard for measurement of sodium in-
take [23]. However, 24-hour urine collections carry a
high participant burden and are prone to under- and
over-collection and low response rates [28]. In contrast,
single urinary sodium collections carry a low participant
burden and may provide a reasonable estimate of the so-
dium intake of a group [29]. Mid-stream urine samplesare collected in standard clinical urine lab containers. Five
millilitres of the urine sample is transferred to a labelled,
10 mL freestanding tube and stored in a secure −4°C
freezer. Frozen samples are couriered in batches to a certi-
fied laboratory and converted to predicted 24-hour urin-
ary sodium excretion using the INTERSALT formula [30].
Data on use and acceptability of the SaltSwitch app is
collected from main household shoppers via an online
questionnaire. The use of the app is assessed for each week
of the intervention phase using a four-point scale ranging
from ‘Used every time I shopped’ to ‘Not at all’. Acceptabil-
ity is assessed via three questions. The first asks how easy
the app was to use on a five-point scale from ‘Very easy’
to ‘Very difficult’; the second and third are open-ended
questions asking what they liked most/least about the app,
and whether or not they think the app is a good way to
help people with CVD to make lower-salt food choices
(and why). Data on serious adverse events are collected at
six and 12 weeks, regardless of causal relationship to the
treatment.
Statistical analyses
Statistical analyses will be performed using SAS version
9.3 (SAS Institute Inc. Cary NC, USA). All statistical
tests will be two-sided and a 5% significance level main-
tained throughout the analyses. Baseline characteristics
will be summarised using descriptive statistics by treat-
ment groups and overall. Continuous variables will be de-
scribed as numbers of observed values, mean ± standard
deviation. Categorical variables will be described as num-
bers and percentages. Since any differences between ran-
domised groups at baseline could only have occurred by
chance, no formal significance testing will be conducted.
Treatment evaluation will be performed on the principle
of intention-to-treat (ITT), using data collected from all
randomised participants. Missing outcome data will not
be imputed, as it is difficult to make assumptions about
the missingness of supermarket till receipt data, or the dir-
ection of the imputed values. Those randomised partici-
pants who are considered compliant to the study protocol
will be included in a secondary per protocol (PP) analysis.
Those households with at least three shopping episodes
during the 4-week intervention period (seven or more
shopping episodes during the 12-week intervention period
for sub-study 2), with a total weekly spend of $25 or more
per person, will be considered compliant. Analysis of co-
variance (ANCOVA) regression models will be used to
evaluate the main treatment effect on the primary out-
come, adjusting for baseline outcome measures; ethnicity,
age, and gender. Model-adjusted means and their differ-
ence between the two treatment groups will be estimated
and tested. A similar approach will be used for other con-
tinuous secondary outcomes, measured at the end of inter-
vention period. Generalized linear models will be applied
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statistical analysis plan outlines all planned analyses and
statistical methods.
Discussion
The SaltSwitch trial is a robust randomized controlled
trial of the short-term (four-week) effects of a promising
mobile health intervention to reduce secondary heart
disease. The trial is designed to maximize internal validity
and is well-powered for the primary outcome (salt content
of food purchases made by households). If found to be ef-
fective, SaltSwitch has potential to improve population
health in New Zealand and globally; CVD is the leading
cause of early death and disability worldwide [1], and
population salt intakes in many countries far exceed
WHO guidelines [8,9,31,32]. Furthermore, the majority of
salt consumed comes from packaged foods [33], which
are the focus of the SaltSwitch app, and smartphone own-
ership is rapidly increasing, particularly in high income
countries [14].
Nonetheless, the current SaltSwitch trial is not pow-
ered to explore effects amongst high risk groups in New
Zealand, including Māori, Pacific, and those on low in-
comes. Moreover, the long term health impacts of the
app for people with CVD and its effectiveness for pri-
mary prevention, are yet to be explored. However, these
questions could be explored in future trials, and the
findings of the current SaltSwitch trial will contribute
significantly to the growing evidence base for the effect-
iveness of smartphone interventions; while there are sev-
eral smartphone apps available on the market for people
with CVD and other non-communicable diseases, the
majority are not evidence-based [1,34,35].
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